Boston Startup Helios Emerges From Stealth With AI-Powered Blood Testing Platform

0
12
Omar Abudayyeh, Ph.D.

BOSTON–Helios Intelligence, a health technology startup backed by Y Combinator and Formation VC, has emerged from stealth with plans to launch an at-home blood testing platform that uses artificial intelligence and protein analysis to provide insights into aging and potential future health risks.

The company announced Wednesday that its testing system will measure more than 1,000 proteins from a single drop of blood, using proteomics technology to analyze biological changes associated with aging and disease.

Helios plans to launch the service in 2027 and has opened a waitlist for prospective customers.

The platform will combine at-home blood collection with an AI-powered health coaching system designed to translate test results into personalized recommendations involving nutrition, lifestyle, supplements and follow-up medical care.

According to the company, users will be able to collect blood samples themselves using a needle-free device, eliminating the need for traditional laboratory blood draws.

“By the time you feel something is wrong, your biology may have been changing for years,” said Omar Abudayyeh, Ph.D., Co-Founder of Helios. “Helios gives people the world’s highest-resolution picture of their health: where they are today, where they’re headed decades from now, and the power to change it.”

Unlike conventional blood tests that typically measure a limited number of biomarkers to identify existing medical conditions, Helios aims to analyze a broader range of proteins circulating in the bloodstream.

These proteins can provide information about biological activity in cells, tissues and organs, potentially helping researchers and clinicians identify patterns associated with disease development and aging.

Research involving blood-based proteomics has linked certain protein patterns to the development of hundreds of diseases, sometimes years before clinical symptoms appear.

Helios intends to apply these findings to consumer health monitoring, offering users a more detailed picture of their biological health and how it may change over time.

The company’s AI Health Coach will interpret the results and provide recommendations based on published scientific research.

“Measurement only matters if it changes what you do next,” said Yousef Badran, M.D., Co-Founder of Helios. “For too long, we’ve treated health data as an endpoint rather than a starting point. We built Helios around a different idea: that understanding what’s happening inside the body should lead to more informed, personalized decisions about what comes next.”

The startup is entering a growing field of companies using artificial intelligence, molecular diagnostics and biological data to develop tools for preventive health care and longevity research.

While proteomics has traditionally been used in academic research and specialized laboratories, advances in molecular analysis are creating opportunities to make the technology more accessible.

Helios plans to expand its platform beyond blood protein measurements by incorporating electronic medical records and data from wearable health devices.

The company also intends to develop AI foundation models trained on biological information to explore how different lifestyle and medical interventions might influence long-term health outcomes.

As users contribute additional health information and new research becomes available, the company expects its models to generate more detailed and individualized recommendations.

“In our quickly moving world, AI-enabled health insights should be able to match the speed that our own health changes,” said Jonathan Gootenberg, Ph.D., Co-Founder of Helios. “Helios embodies the idea that increasing amounts of data will lead to unparalleled control over our future health, eventually pushing disease from ‘soon’ to ‘never.'”

Although the company is positioning its technology as a way to identify health risks years or decades in advance, the announcement did not include clinical validation data demonstrating the predictive accuracy of its specific testing platform.

The company is led by researchers and entrepreneurs with backgrounds in biotechnology, molecular diagnostics and digital health.

Co-Founders Abudayyeh and Gootenberg previously conducted research at Harvard University and the Massachusetts Institute of Technology, where they helped advance CRISPR-based diagnostic technologies.

The two scientists also co-founded Sherlock Biosciences, which developed the first FDA-authorized CRISPR-based diagnostic test, along with Proof Diagnostics and Tome Biosciences.

Badran is a Physician-Scientist at Massachusetts General Hospital specializing in gastroenterology and internal medicine. His background includes drug development and digital health.

According to Helios, its founders have collectively raised more than $700 million in funding through their previous companies.

Helios is backed by Y Combinator’s Winter 2026 cohort, Formation VC and a group of investors, technology entrepreneurs and physicians.

The company has not disclosed the amount of funding raised specifically for Helios.

With its planned 2027 launch, Helios aims to bring advanced protein analysis into home-based health monitoring while using artificial intelligence to help individuals better understand their biological health and potential disease risks.

Leave A Reply

Please enter your comment!
Please enter your name here